Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant LDRT, Chemotherapy and Durvalumab in Stage III NSCLC
NCT05157542Phase 1Unknown
- Start
- Jun 2021
- Primary completion
- Jun 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of durvalumab in non-small cell lung cancer (NSCLC) (3 cohorts). Primary endpoint: Incidence of treatment-emergent adverse events up to 36 months. Status: unknown.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05157542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05157542.